Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04081259 · ClinicalTrials.gov registry record · Phase 1

LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy

A Phase 1 study of Acute Myeloid Leukemia, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
Phase 1
Development phase
17
Enrollment target
1
Study location

NCT04081259 is a Phase 1 study of Acute Myeloid Leukemia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 17 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04081259, a Phase 1 study of Acute Myeloid Leukemia, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
Phase 1
Development phase
17 participants
Enrollment target
1
Study location

Study Summary

This research study is evaluating a targeted therapy as a possible treatment for acute myeloid leukemia (AML) that has returned or not responded to standard treatment.

Conditions Studied

Acute Myeloid Leukemia

Interventions

  • DRUG LY3214996

Study Locations (1)

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2020-07-15
Est. Completion 2023-08-26
Phase Phase 1

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04081259

The ClinicalTrials.gov registry entry for NCT04081259 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (85% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which LY3214996 is the first listed.

NCT04081259 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04081259 about?

NCT04081259 is a clinical study titled "LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy". This research study is evaluating a targeted therapy as a possible treatment for acute myeloid leukemia (AML) that has returned or not responded to standard treatment.

What is the current status of trial NCT04081259?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2020-07-15. Estimated completion is 2023-08-26.

What conditions does trial NCT04081259 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia.

What interventions are being tested in trial NCT04081259?

The interventions under investigation include: LY3214996 (DRUG).

Who is sponsoring clinical trial NCT04081259?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04081259 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.